CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IO скачать в хорошем качестве

CheckMate 816: addressing unanswered questions on surgical outcomes following neoadjuvant chemo-IO

Jonathan Spicer, MD, PhD, McGill University, Montreal, Canada, talks on the importance of the CheckMate 816 (NCT02998528) trial, a Phase III study evaluating nivolumab plus platinum-doublet chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). In recent years, there has been a growing interest in the use of neoadjuvant approaches in lung cancer and its impact on pathologic complete response and survival outcomes. However, many questions have been raised about the implications of novel neoadjuvant treatments on surgical outcomes. Checkmate 816 is the first Phase III multicenter randomized controlled trial of chemotherapy vs. chemo-immunotherapy (IO) in patients with operable NSCLC to report surgical outcomes. The findings, reported at ASCO 2021, have the potential to address many of the unknowns in this field. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.